Published in Gastroenterology on February 01, 2000
Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol (2001) 4.48
T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature (2015) 3.06
Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol (2002) 1.81
Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology (2010) 1.59
Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol (2005) 1.54
Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest (2014) 1.54
Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol (2002) 1.51
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol (2002) 1.40
Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines (2011) 1.37
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol (2013) 1.35
Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology (2008) 1.31
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A (2003) 1.26
Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol (2008) 1.22
Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma (2010) 1.20
Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis (2004) 1.20
Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol (2007) 1.17
Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection. J Virol (2004) 1.14
Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol (2007) 1.10
Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. J Virol (2005) 1.03
Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol (2006) 1.02
Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother (2004) 1.00
Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol (2007) 0.99
Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C. PLoS One (2012) 0.96
Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol (2002) 0.93
Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunity. Eur J Immunol (2012) 0.92
The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels. Antimicrob Agents Chemother (2000) 0.92
Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat (2008) 0.92
Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol (2008) 0.92
The evolutionary dynamics of a rapidly mutating virus within and between hosts: the case of hepatitis C virus. PLoS Comput Biol (2009) 0.91
Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N Y) (2007) 0.89
Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS (2005) 0.89
Viral escape mechanisms--escapology taught by viruses. Int J Exp Pathol (2001) 0.89
HCV genotype-3a T cell immunity: specificity, function and impact of therapy. Gut (2012) 0.86
Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol (2003) 0.86
Effects of HCV treatment on cytokine expression during HCV/HIV coinfection. J Interferon Cytokine Res (2006) 0.86
IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2011) 0.86
The role of CCR5 in HCV infection. Eur J Med Res (2010) 0.84
Dysfunction of Immune Systems and Host Genetic Factors in Hepatitis C Virus Infection with Persistent Normal ALT. Hepat Res Treat (2011) 0.81
Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers. J Immune Based Ther Vaccines (2008) 0.81
Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases. Proc Natl Acad Sci U S A (2007) 0.80
Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C. Antimicrob Agents Chemother (2008) 0.79
Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat (2010) 0.79
Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy. J Gastroenterol (2012) 0.78
PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C. PLoS One (2014) 0.78
Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection. J Viral Hepat (2013) 0.77
Synthetic antigens representing the antigenic variation of human hepatitis C virus. Viral Immunol (2010) 0.77
Association between low molecular polypeptide 7 single nucleotide polymorphism and response to therapy in hepatitis C virus infection. World J Hepatol (2013) 0.77
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. Clin Exp Immunol (2004) 0.76
Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat (2011) 0.76
Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol (2016) 0.75
Bell's palsy and choreiform movements during peginterferon alpha and ribavirin therapy. World J Gastroenterol (2009) 0.75
Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C. World J Gastroenterol (2003) 0.75
Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol (2015) 0.75
Tracking TCRβ Sequence Clonotype Expansions during Antiviral Therapy Using High-Throughput Sequencing of the Hypervariable Region. Front Immunol (2016) 0.75
Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. J Clin Transl Hepatol (2016) 0.75
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Liver in Felty's syndrome. Br Med J (1970) 2.75
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
Liver transplantation. Curr Probl Surg (1979) 2.57
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
The systemic inflammatory response syndrome in acute liver failure. Hepatology (2000) 2.47
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Attentional bias in anxiety and depression: the role of awareness. Br J Clin Psychol (1995) 2.43
Developing and deploying a patient safety program in a large health care delivery system: you can't fix what you don't know about. Jt Comm J Qual Improv (2001) 2.42
Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 2.41
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
1 -Antitrypsin deficiency and neonatal hepatitis. Br Med J (1972) 2.40
General practice orthopaedic outpatient referrals in North Staffordshire. Br Med J (Clin Res Ed) (1983) 2.38
Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol (1992) 2.31
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet (1982) 2.30
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs. Lancet (1970) 2.25
Cytomegalovirus hepatitis in the adult. Lancet (1967) 2.20
Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ (1990) 2.18
Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain. Lancet (1973) 2.17
Assessment of non-mydriatic fundus photography in detection of diabetic retinopathy. Br Med J (Clin Res Ed) (1986) 2.16
Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care (1999) 2.16
Portal hypertension in idiopathic tropical splenomegaly. Lancet (1966) 2.16
Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet (1968) 2.14
Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J Biol Chem (1989) 2.14
Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax (2002) 2.12
A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology (1995) 2.11
H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trials. Lancet (1977) 2.10
Reduction of absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure. Br Med J (1973) 2.09
Arthropathy of haemochromatosis. Clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis (1970) 2.09
Detection, treatment, and follow up of women with Chlamydia trachomatis infection seeking abortion in inner city general practices. BMJ (1989) 2.08
Early and intensive therapy of intravascular coagulation in acute liver failure. Lancet (1971) 2.08
Simple hypothermic preservation for transporting human livers long distances for transplantation. Report of 12 cases. Transplantation (1977) 2.08
Cell-mediated immune responses in chronic liver diseases. Br Med J (1972) 2.05
Inheritance and expression of chimeric genes in the progeny of transgenic maize plants. Biotechnology (N Y) (1990) 2.05
Chondrocalcinosis and arthropathy: studies in haemochromatosis and in idiopathic chondrocalcinosis. Q J Med (1970) 2.03
Development and importance of health needs assessment. BMJ (1998) 2.03
Hereditary spherocytosis with secondary haemochromatosis. Lancet (1968) 2.00
Liver transplantation in man: the frequency of rejection, biliary tract complications, and recurrence of malignancy based on an analysis of 26 cases. Gastroenterology (1973) 1.99
Evidence that hepatitis D virus needs hepatitis B virus to cause hepatocellular damage. Am J Clin Pathol (1992) 1.98
Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med (1976) 1.98
Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet (1974) 1.97
Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet (1982) 1.97
Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction? Br Med J (1972) 1.95
Causal attributions and psychiatric symptoms in survivors of the Herald of Free Enterprise disaster. Br J Psychiatry (1991) 1.95